首页> 外文OA文献 >Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors

【2h】

Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors

机译：盐酸三胞苷（ILX651），第三代偶像酰-15的阶段I和药代动力学研究，每28天每28天施用3周，治疗晚期实体肿瘤

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Alain C. Mita; Lisa A. Hammond; Peter L. Bonate; Geoffrey Weiss; Heather McCreery; Samira Syed; Mitchell Garrison; Quincy S.C. Chu; Johann S. DeBono; Christopher B. Jones; Steve Weitman; Eric K. Rowinsky;
展开▼
作者单位

展开▼
年度 2006
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. [J] . Moore M, Hirte HW, Siu L, Annals of oncology: official journal of the European Society for Medical Oncology . 2005,第10期

机译：一期研究旨在确定新型Raf激酶和VEGFR抑制剂BAY 43-9006的安全性和药代动力学，该药物在患有晚期难治性实体瘤的患者中开28天/休7天。
2. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors [J] . Howard A. Burris III, Suzanne F. Jones, Daphne D. Williams, Investigational New Drugs . 2011,第3期

机译：Ispinesib（一种驱动蛋白纺锤体蛋白抑制剂）的I期研究在实体瘤患者中连续28周每天连续3周每周给药3周
3. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors. [J] . Burris HA 3rd, Jones SF, Williams DD, Investigational new drugs. . 2011,第3期

机译：对Ispinesib（一种驱动蛋白纺锤体蛋白抑制剂）进行的I期研究在患有实体瘤的患者中连续28周每天连续3周，每周3次。
4. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
5. Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1–5 of a 3-weekly cycle in patients with advanced solid tumours [O] . M J A de Jonge, S Kaye, J Verweij, 2004

机译：口服实体拓扑异构酶I和II抑制剂XR11576的I期和药代动力学研究在晚期实体瘤患者的3周周期中的第1-5天进行

Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors

著录项

相似文献

相关主题

期刊订阅